Dual detection capability
Both infection-induced and vaccine-induced antibodies1
Dual detection capability
Both infection-induced and vaccine-induced antibodies1
Multiple applications
Seroprevalence, clinical settings, research
Specific target
S1 subunit of Spike protein
Ongoing relevance
Virus still circulating post-pandemic
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the Betacoronavirus that emerged in late 2019, caused the global outbreak known as COVID-19. Although the pandemic phase ended in 2023, the virus continues to circulate alongside other respiratory pathogens. Ongoing seroprevalence monitoring remains important to understand both vaccine-induced and infection-induced immunity over time.
SARS-CoV-2 antibodies can be detected in individuals who have recovered from infection or who have been vaccinated.1 Reliable laboratory testing is essential for evaluating antibody levels in serosurveillance, clinical settings, and research studies.
References
For in vitro diagnostic use. For emergency use authorization only.
2026 Euroimmun US
Privacy Policy | Website Terms and Conditions | Cookie Notice and Settings | Consent Preferences | Sitemap